Antibody production in patients hospitalized with COVID-19

Antibody production in patients hospitalized with COVID-19
Credit: Mary Ann Liebert, Inc., publishers

Antibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COVID-19, according to a study published in the peer-reviewed journal Viral Immunology.

Diane Griffin, MD, Ph.D., from Johns Hopkins Bloomberg School of Public Health, and coauthors, analyzed the blood of 55 hospitalized up to four months after onset of COVID-19 symptoms. They reported spike (S)- and nucleocapsid (N)-specific IgM and IgG ASCs within two weeks.

The investigators found that: "Patients with more produced more S-specific IgM and IgG ASCs than those with mild disease and had higher levels of both N- and S-specific antibody in ." The findings predict a more durable immune response in patients recovering from more severe disease.

"This is a highly relevant and timely article because it provides scientific insights into the contribution of SARS-CoV-2 immunity gained from natural infection. The level of immunity potentially generated from actual infection with the has been a topic of intense debate since the beginning of the pandemic," says Rodney S. Russell, Ph.D., Editor-in-Chief of Viral Immunology, from Memorial University of Newfoundland, St. John's.

More information: Maggie L. Bartlett et al, Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19, Viral Immunology (2022). DOI: 10.1089/vim.2021.0191

Citation: Antibody production in patients hospitalized with COVID-19 (2022, March 25) retrieved 16 July 2024 from https://medicalxpress.com/news/2022-03-antibody-production-patients-hospitalized-covid-.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New thesis on B cell responses to SARS-CoV-2

14 shares

Feedback to editors